Go Pro
→ Buy this stock tomorrow morning (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$2.24
-1.8%		$1.72
$0.82
▼
$3.79
$19.27M0.7314.09 million shs482,978 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.03
+3.7%		$1.03
$0.76
▼
$3.31
$77.30M1.46687,929 shs838,846 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.51
-0.7%		$1.55
$1.34
▼
$3.20
$79.77M0.0369,787 shs22,266 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.10
-1.8%		$1.18
$0.89
▼
$2.09
$77.03M-0.2554,379 shs19,546 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
-1.75%+7.18%+47.37%+35.76%+47.37%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+3.66%+0.98%+20.41%-26.43%-50.95%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-0.66%-3.21%-10.12%-9.04%-35.74%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-1.79%-6.78%-9.09%-10.57%-16.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$2.24
-1.8%		$1.72
$0.82
▼
$3.79
$19.27M0.7314.09 million shs482,978 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$1.03
+3.7%		$1.03
$0.76
▼
$3.31
$77.30M1.46687,929 shs838,846 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$1.51
-0.7%		$1.55
$1.34
▼
$3.20
$79.77M0.0369,787 shs22,266 shs
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
$1.10
-1.8%		$1.18
$0.89
▼
$2.09
$77.03M-0.2554,379 shs19,546 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
-1.75%+7.18%+47.37%+35.76%+47.37%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+3.66%+0.98%+20.41%-26.43%-50.95%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-0.66%-3.21%-10.12%-9.04%-35.74%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-1.79%-6.78%-9.09%-10.57%-16.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
1.00
SellN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.14
Hold$7.50628.16% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.40
Hold$5.67275.28% Upside
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest BIVI, CRDF, OKYO, and TELO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/19/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/11/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
8/5/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/21/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/17/2026
BioVie Inc. stock logo
BIVI
BioVie
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$7.00 ➝ $5.00
6/3/2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$2.00
(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$1.22 per shareN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$590K135.80N/AN/A$0.34 per share3.03
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A$0.30 per shareN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/A$0.07 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$22.07M-$3.15N/AN/AN/AN/A-126.02%-108.88%11/9/2026 (Estimated)
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.85M-$0.60N/AN/AN/A-7,885.43%-103.10%-75.52%11/5/2026 (Estimated)
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$8.95MN/AN/AN/AN/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$10.41M-$0.91N/AN/AN/AN/A-102.70%-90.75%9/2/2026 (Estimated)

Latest BIVI, CRDF, OKYO, and TELO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/2/2026N/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
-$0.07-$0.79-$0.72-$0.79N/AN/A
8/12/2026Q4 2026
BioVie Inc. stock logo
BIVI
BioVie
-$0.52-$0.70-$0.18-$0.70N/AN/A
8/11/2026Q2 2026
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.1196-$0.14-$0.0204-$0.14$0.06 million$0.10 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
3.59
3.59
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
3.30
3.30
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/A
2.43
2.43
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A
16.16
16.16

Institutional Ownership

CompanyInstitutional Ownership
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
2.97%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
BioVie Inc. stock logo
BIVI
BioVie
0.90%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
8.80%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
40.46%
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
16.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
108.45 million8.38 millionNo Data
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2077.79 million70.95 millionOptionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
752.48 million31.25 millionNot Optionable
Telomir Pharmaceuticals, Inc. stock logo
TELO
Telomir Pharmaceuticals
168.78 million57.52 millionN/A

Recent News About These Companies

Telomir Pharmaceuticals (TELO) Expected to Announce Quarterly Earnings on Wednesday
August 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30983408
Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/upcoming-telomir-pharmaceuticals-telo-to-post-quarterly-earnings-on-wednesday-2026-08-26/
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-releases-quarterly-earnings-results-2026-08-13/
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?
August 12, 2026  |  defenseworld.netD
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% - Should You Sell?
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/telomir-pharmaceuticals-nasdaqtelo-stock-price-down-34-should-you-sell-2026-08-12/
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/telomir-announces-peer-reviewed-publication-demonstrating-telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models-1036435451
Telomir-Zn Preclinical Data Support Advancement in TNBC
August 10, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-support-advancement-in-tnbc?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models
August 10, 2026  |  quiverquant.comQ
TELO Telomir Pharmaceuticals, Inc.
July 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/TELO
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...
June 15, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/34770/telomir-pharmaceuticals-announces-peer-reviewed-publication-in-biomedicine-pharmacotherapy-demonstrating-restoration-of-insulin-sensitivity-with-telomir-zn-in-a-preclinical-type-2-diabetes-model/
Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data
June 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-showcases-preclinical-telomir-zn-diabetes-efficacy-data?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
June 15, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Appoints Fractional CFO After Leadership Change
June 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-appoints-fractional-cfo-after-leadership-change?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Inc TELO
May 26, 2026  |  morningstar.comM
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s Disease
May 20, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/32948/telomir-pharmaceuticals-reports-peer-reviewed-publication-of-telomir-zn-data-demonstrating-improved-survival-and-multiple-endpoint-benefits-in-wilsons-disease/
Telomir-Zn Preclinical Data Published in Wilson’s Disease
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-zn-preclinical-data-published-in-wilsons-disease?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
May 20, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Receives FDA IND Clearance for Telomir-Zn
April 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-receives-fda-ind-clearance-for-telomir-zn?utm_source=marketbeat.com&utm_medium=referral
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
April 30, 2026  |  accessnewswire.comA
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
April 24, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/31216/telomir-pharmaceuticals-completes-acquisition-of-teli-pharmaceuticals-securing-global-rights-to-telomir-1-telomir-zn/
Telomir Pharmaceuticals Inc.
April 2, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/telo/research-ratings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioVie stock logo

BioVie NASDAQ:BIVI

$2.24 -0.04 (-1.75%)
Closing price 09/1/2026 04:00 PM Eastern
Extended Trading
$2.23 -0.01 (-0.40%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$1.03 +0.04 (+3.66%)
Closing price 09/1/2026 04:00 PM Eastern
Extended Trading
$1.00 -0.03 (-2.43%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$1.51 -0.01 (-0.66%)
Closing price 09/1/2026 04:00 PM Eastern
Extended Trading
$1.51 0.00 (0.00%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Telomir Pharmaceuticals stock logo

Telomir Pharmaceuticals NASDAQ:TELO

$1.10 -0.02 (-1.79%)
Closing price 09/1/2026 04:00 PM Eastern
Extended Trading
$1.12 +0.02 (+1.91%)
As of 07:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas